We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Sanofi (SNY) Stock Sinks As Market Gains: What You Should Know
Read MoreHide Full Article
In the latest trading session, Sanofi (SNY - Free Report) closed at $48.63, marking a -0.92% move from the previous day. This move lagged the S&P 500's daily gain of 1.19%. Meanwhile, the Dow gained 0.76%, and the Nasdaq, a tech-heavy index, added 0.29%.
Heading into today, shares of the drugmaker had gained 1.15% over the past month, outpacing the Medical sector's gain of 0.84% and lagging the S&P 500's gain of 4.06% in that time.
Wall Street will be looking for positivity from Sanofi as it approaches its next earnings report date. This is expected to be February 3, 2023. In that report, analysts expect Sanofi to post earnings of $0.90 per share. This would mark year-over-year growth of 13.92%. Meanwhile, our latest consensus estimate is calling for revenue of $11.51 billion, up 0.68% from the prior-year quarter.
It is also important to note the recent changes to analyst estimates for Sanofi. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 2.26% higher. Sanofi is currently sporting a Zacks Rank of #2 (Buy).
In terms of valuation, Sanofi is currently trading at a Forward P/E ratio of 11.15. Its industry sports an average Forward P/E of 14.63, so we one might conclude that Sanofi is trading at a discount comparatively.
Meanwhile, SNY's PEG ratio is currently 1.15. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. SNY's industry had an average PEG ratio of 1.8 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 46, which puts it in the top 19% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Sanofi (SNY) Stock Sinks As Market Gains: What You Should Know
In the latest trading session, Sanofi (SNY - Free Report) closed at $48.63, marking a -0.92% move from the previous day. This move lagged the S&P 500's daily gain of 1.19%. Meanwhile, the Dow gained 0.76%, and the Nasdaq, a tech-heavy index, added 0.29%.
Heading into today, shares of the drugmaker had gained 1.15% over the past month, outpacing the Medical sector's gain of 0.84% and lagging the S&P 500's gain of 4.06% in that time.
Wall Street will be looking for positivity from Sanofi as it approaches its next earnings report date. This is expected to be February 3, 2023. In that report, analysts expect Sanofi to post earnings of $0.90 per share. This would mark year-over-year growth of 13.92%. Meanwhile, our latest consensus estimate is calling for revenue of $11.51 billion, up 0.68% from the prior-year quarter.
It is also important to note the recent changes to analyst estimates for Sanofi. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 2.26% higher. Sanofi is currently sporting a Zacks Rank of #2 (Buy).
In terms of valuation, Sanofi is currently trading at a Forward P/E ratio of 11.15. Its industry sports an average Forward P/E of 14.63, so we one might conclude that Sanofi is trading at a discount comparatively.
Meanwhile, SNY's PEG ratio is currently 1.15. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. SNY's industry had an average PEG ratio of 1.8 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 46, which puts it in the top 19% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.